Compare RDIB & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDIB | EMBC |
|---|---|---|
| Founded | 1937 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.5M | 328.1M |
| IPO Year | 1994 | 2021 |
| Metric | RDIB | EMBC |
|---|---|---|
| Price | $11.21 | $6.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 8.2K | ★ 836.9K |
| Earning Date | 11-13-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ 60.76 | 20.90 |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $202,988,000.00 | N/A |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.04 | $5.59 |
| P/E Ratio | ★ N/A | $6.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.00 | $2.77 |
| 52 Week High | $24.00 | $14.91 |
| Indicator | RDIB | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 67.69 |
| Support Level | $10.28 | $3.01 |
| Resistance Level | $12.59 | $9.38 |
| Average True Range (ATR) | 0.62 | 0.28 |
| MACD | -0.32 | 0.05 |
| Stochastic Oscillator | 3.78 | 84.15 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.